Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire July 7, 2015

Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA

GlobeNewswire June 5, 2015

Genmab Gains License to Antibody Panel Targeting CD19

GlobeNewswire June 2, 2015

Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA

GlobeNewswire May 21, 2015

Genmab Enters Commercial DuoBody(r) Technology Agreement With BioNTech in Field of Immuno-oncology

GlobeNewswire May 19, 2015

HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting

GlobeNewswire May 13, 2015

Genmab Announces Financial Results for the First Quarter of 2015

GlobeNewswire May 12, 2015

First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)

GlobeNewswire May 6, 2015

Genmab Announces Phase III Study of Arzerra(r) Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL

GlobeNewswire April 27, 2015

Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire April 16, 2015

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab

GlobeNewswire March 26, 2015

Genmab Acquires Antibody Assets from iDD Biotech

GlobeNewswire March 18, 2015

Genmab Retains Partial Rights for HuMax-TAC-ADC - Will Not Exercise Co-development Right

GlobeNewswire March 16, 2015

Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015

GlobeNewswire March 11, 2015

Genmab 2014 Annual Report

GlobeNewswire March 2, 2015

Genmab Announces That Agreement to Transfer Ofatumumab Collaboration to Novartis is Now Effective

GlobeNewswire March 2, 2015

Genmab Enters Commercial DuoBody Technology Agreement with BioNovion in the Field of Immuno-Oncology

GlobeNewswire February 19, 2015

Major Shareholder Announcement

GlobeNewswire February 4, 2015

Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)

GlobeNewswire February 4, 2015

Genmab Announces Preliminary Results in Phase II Study of Daratumumab in Double Refractory Multiple Myeloma

GlobeNewswire February 3, 2015